Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRLHR | P49683 | 4/20 | 0.47 |
| ▸ | CLPP | Q16740 | 2/20 | 0.41 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22424544 | 0.88 | PRLHR (0.49) | PRLHRCLPPMTHFD2LMNAMAPT | |
| SCHEMBL22424690 | 0.87 | PRLHR (0.49) | PRLHRLMNAMAPTALDH1A1GRM1 | |
| SCHEMBL22424388 | 0.86 | PRLHR (0.47) | PRLHRLMNAMAPTALDH1A1 | |
| SCHEMBL22410896 | 0.84 | PRLHR (0.49) | PRLHRLMNAMAPTALDH1A1POLB | |
| SCHEMBL22423999 | 0.84 | PRLHR (0.50) | PRLHRCLPPMTHFD2LMNAMAPT | |
| SCHEMBL22424572 | 0.84 | PRLHR (0.47) | PRLHRLMNAMAPTALDH1A1GAA | |
| SCHEMBL22424283 | 0.84 | PRLHR (0.50) | PRLHRCLPPLMNAMAPT | |
| SCHEMBL22423960 | 0.84 | PRLHR (0.48) | PRLHRLMNAMAPTALDH1A1POLB | |
| SCHEMBL22424014 | 0.83 | PRLHR (0.51) | PRLHRCLPPLMNAMAPTALDH1A1 | |
| SCHEMBL22424139 | 0.83 | PRLHR (0.49) | PRLHRLMNAMAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020182990-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-17 | — | — | WO | disclosed |